Hebei Changshan Biochemical Hits Day High with 4.65% Surge

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. has experienced a notable increase of 4.65% on August 13, 2026, reaching an intraday high of CNY 29.16. This performance stands in contrast to the China Shanghai Composite, which declined by 0.5% on the same day. Over the past week, Hebei Changshan has shown a robust gain of 9.59%, and its monthly performance reflects an increase of 11.88%. Despite these short-term gains, the company has faced significant challenges over the longer term. Its one-year performance shows a decline of 41.32%, and year-to-date, it has dropped by 54.35%. In the last three years, however, the stock has demonstrated impressive growth of 432.89%, indicating a complex performance trajectory. Financially, Hebei Changshan is currently net-debt free, but it has reported negative results for the last four consecutive quarters, with a net profit of CNY -322.94 million. The company’s return on equity stands at -30.22%, and it has a price-to-book ratio of 21.26. As a large-cap player in the pharmaceuticals and biotechnology sector, Hebei Changshan continues to navigate a challenging market landscape.